A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Cancer
; 126(6): 1264-1273, 2020 03 15.
Article
in En
| MEDLINE
| ID: mdl-31860140
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Acute
/
Antineoplastic Combined Chemotherapy Protocols
/
Immunoconjugates
/
Induction Chemotherapy
/
Antineoplastic Agents, Immunological
/
Brentuximab Vedotin
Type of study:
Prognostic_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2020
Type:
Article